Pimecrolimus, yet another intriguing topical immunomodulator

Abstract

Pimecrolimus, yet another intriguing local immunomodulator, has been approved for use in atopic dermatitis in individuals of more then 2 years of age. However, its indications are now being extended to include a variety of inflammatory dermatoses, which are identified in the current article with a proviso that their use should be considered only as an alternative when conventional modalities have failed.

• Pimecrolimus
• tacrolimus